Saltar al contenido
Merck

M0195

Sigma-Aldrich

MAPKAPK2

recombinant, expressed in HEK 293 cells, ≥60 units/mg protein, buffered aqueous glycerol solution

Sinónimos:

MAP kinase activated protein kinase 2, MAPKAP Kinase 2 human

Iniciar sesiónpara Ver la Fijación de precios por contrato y de la organización


About This Item

MDL number:
UNSPSC Code:
12352200
NACRES:
NA.32

recombinant

expressed in HEK 293 cells

Quality Level

form

buffered aqueous glycerol solution

specific activity

≥60 units/mg protein

mol wt

45-60 kDa

UniProt accession no.

shipped in

dry ice

storage temp.

−70°C

Gene Information

human ... MAPKAPK2(9261)

Biochem/physiol Actions

MAPKAPK2 is a serine/threonine protein kinase activated by the p38 MAP kinase in response to various signals including mitogenic and stress stimuli. MAPKAPK2 is distinguished from the RSK family of ribosomal protein S6 kinases (also termed MAPKAPK1), which are activated by the MAP kinases, ERK1, and ERK2 based on its substrate specificity and amino acid sequence. Upon activation, p38 MAP kinase activates the downstream MAPKAPK2 by phosphorylation of the threonine residue in the Pro-Thr motif in response to heat shock or mitogenic stimuli. Activated MAPKAPK2 phosphorylates the small heat shock protein HSP25/HSP27, both in vitro and in vivo, at serine residues. Thus, HSP25/HSP27 seems to be the physiological substrate of MAPKAPK2.

Unit Definition

One unit will incorporate 1.0 nmole of phosphate into HSP 25 per minute at 30 °C at pH 7.4.

Physical form

Solution in 50 mM Tris-HCl, pH 7.4, 100 mM NaCl, 0.05 mM EDTA, 2 mM DTT, and 10% glycerol.

Storage Class

10 - Combustible liquids

wgk_germany

WGK 1

flash_point_f

Not applicable

flash_point_c

Not applicable


Certificados de análisis (COA)

Busque Certificados de análisis (COA) introduciendo el número de lote del producto. Los números de lote se encuentran en la etiqueta del producto después de las palabras «Lot» o «Batch»

¿Ya tiene este producto?

Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.

Visite la Librería de documentos

Sung-Jen Wei et al.
Cell death & disease, 11(5), 368-368 (2020-05-16)
Despite the improvement in clinical outcome with 13-cis-retinoic acid (13-cisRA) + anti-GD2 antibody + cytokine immunotherapy given in first response ~40% of high-risk neuroblastoma patients die of recurrent disease. MYCN genomic amplification is a biomarker of aggressive tumors in the

Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.

Póngase en contacto con el Servicio técnico